Self-expanding stents improve positioning in primary angioplasty

Original title: Self-Expanding Versus Balloon-Expandable Stents in Acute Myocardial Infarction: Results From the APPOSITION II Study Reference: Robert-Jan van Geuns et al. J Am Coll Cardiol Intv 2012;5:1209–19

Acute myocardial infarction is associated with vasoconstriction and thrombus occlusion. Resolution of these two points during the first hours after primary angioplasty can lead to poor extension and poor positioning of the stent implanted with the probable risk of thrombosis and restenosis. 

On the other hand, aggressive implantation could cause distal embolization. This study tested the hypothesis that self-expanding stents are more effective than balloon-expandable stents to reduce poor positioning after primary angioplasty. We randomized 80 patients with ST elevation acute myocardial infarction (STEMI) who were receiving primary angioplasty with a self-expandable stent (STENTYS, Paris, France) or a balloon-expandable stent (Vision, Abbott Vascular, Santa Clara, California, or Driver, Medtronic, Minneapolis, Minnesota). 

The primary endpoint was the proportion of the struts poor positioning after 3 days of implantation using optical coherence tomography (OCT). The secondary endpoint was major cardiac events such as cardiac death, recurrent infarction or emergency bypass surgery. After 3 days of implantation, the self-expanding stents had a lower percentage of poor strut positioning compared with balloon-expandable (0.58% versus 5.46%, respectively, P <0.001). The major cardiac events at 6 months were not significantly different between groups.

Conclusion 

Self-expanding stents had a lower incidence of poor strut positioning using OCT than balloon-expandable stents after primary angioplasty.

Editorial Comment:

This study lacks sufficient power to show the clinical differences between the two types of stent, however it does show the feasibility and safety of self-expanding stents that have already been tested at bifurcations. A particularly striking feature is the lack of data on the degree of TIMI 3 and Blush post implant. 

Courtesy of Dr. Gustavo Hidalgo.
Fellowship of Interventional Cardiology.
Fundación Favaloro.

Dr. Gustavo Hidalgo para SOLACI.ORG

More articles by this author

ACVC 2026 | CELEBRATE Trial: Prehospital Zalunfiban Use in STEMI

Optimizing antithrombotic therapy in the prehospital phase of ST-segment elevation myocardial infarction (STEMI) remains challenging due to the delayed onset of action of P2Y12...

ACVC 2026 | BOX Substudy: Mean Arterial Pressure Targets in Cardiogenic Shock After OHCA

Hemodynamic management of cardiogenic shock following ischemic out-of-hospital cardiac arrest (OHCA-AMICS) remains an unresolved issue, particularly regarding optimal mean arterial pressure (MAP) targets and...

Drugs for the Treatment of No-Reflow During PCI

The no-reflow phenomenon is one of the most frustrating complications of primary angioplasty (pPCI), reflecting persistent microvascular damage that, in the mid- to long-term,...

Rotational atherectomy and its technical secrets: use of floppy or ES guidewire

Rotational atherectomy (RA) remains a very useful tool in the management of severe coronary calcification. However, many of its technical aspects rely more on...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

ACVC 2026 | CELEBRATE Trial: Prehospital Zalunfiban Use in STEMI

Optimizing antithrombotic therapy in the prehospital phase of ST-segment elevation myocardial infarction (STEMI) remains challenging due to the delayed onset of action of P2Y12...

ACVC 2026 | BOX Substudy: Mean Arterial Pressure Targets in Cardiogenic Shock After OHCA

Hemodynamic management of cardiogenic shock following ischemic out-of-hospital cardiac arrest (OHCA-AMICS) remains an unresolved issue, particularly regarding optimal mean arterial pressure (MAP) targets and...

ACVC 2026 | FLASH Registry European Cohort: Mechanical Thrombectomy in Pulmonary Embolism

The management of intermediate-high and high-risk pulmonary embolism (PE) remains an area of therapeutic uncertainty, particularly in patients with right ventricular (RV) dysfunction, in...